HPE Europe 2020: What’s the Impact of Recent Regulation and Government Measures on Investments in Healthcare and Life Sciences in Europe?

Présentation


The impact of COVID-19 triggered recent regulation and government measures on investments in healthcare and life sciences in Europe has been and will continue to be substantial. To move forward stakeholders must understand which changes stand to affect investment opportunities most and which will have long term implications.

Join our panel of industry experts and PE managers during our upcoming webinar, where attendees can expect to learn:

  • How the lockdown and severance and stimulus packages will affect investors’ decisions in health and life sciences in Europe
  • What the impact of accelerated authorization proceedings will be for clinical lab tests, vaccines and drugs in connection with COVID-19
  • How aggravated foreign investment control regimes will impact the health and life sciences sector during COVID-19

To learn more about this series click here.

Speakers


  • Ben Faircloth, Partner and Global Co-head of Healthcare, L.E.K. Consulting
  • Karthic Jayaraman, Partner, TPG Captial
  • Max Müller, Head of Public Affairs Germany & EU, Bayer AG, Formerly CSO of DocMorris
  • Dr. Ulrich Wandschneider, Senior Advisor, Trilantic Capital Partners, Supervisory Board Member, Biontech SE, Formerly CEO of Asklepios Kliniken GmbH & Co.KGaA

MODERATOR

  • Dr. Stephan Rau, Partner, McDermott Will & Emery

Nous contacter